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Research
AbstrACt
Objectives (1) To characterise variation in general 
practitioners’ (GPs’) accounts of communicating with 
men about prostate cancer screening using the prostate-
specific antigen (PSA) test, (2) to characterise GPs’ reasons 
for communicating as they do and (3) to explain why and 
under what conditions GP communication approaches 
vary.
study design and setting A grounded theory study. We 
interviewed 69 GPs consulting in primary care practices in 
Australia (n=40) and the UK (n=29).
results GPs explained their communication practices in 
relation to their primary goals. In Australia, three different 
communication goals were reported: to encourage 
asymptomatic men to either have a PSA test, or not test, or 
alternatively, to support men to make their own decision. 
As well as having different primary goals, GPs aimed to 
provide different information (from comprehensive to 
strongly filtered) and to support men to develop different 
kinds of understanding, from population-level to ‘gist’ 
understanding. Taking into account these three dimensions 
(goals, information, understanding) and building on 
Entwistle et al’s Consider an Offer framework, we derived 
four overarching approaches to communication: Be 
screened, Do not be screened, Analyse and choose, and As 
you wish. We also describe ways in which situational and 
relational factors influenced GPs’ preferred communication 
approach.
Conclusion GPs’ reported approach to communicating 
about prostate cancer screening varies according to three 
dimensions—their primary goal, information provision 
preference and understanding sought—and in response 
to specific practice situations. If GP communication 
about PSA screening is to become more standardised 
in Australia, it is likely that each of these dimensions 
will require attention in policy and practice support 
interventions.
IntrOduCtIOn  
Worldwide, many men undergo regular pros-
tate-specific antigen (PSA) screening for 
prostate cancer risk in primary care. We will 
use PSA screening to refer to PSA testing in 
ostensibly healthy men who are not consid-
ered to be at high risk of prostate cancer for 
their age; this contrasts with PSA testing in 
men who have a diagnosis of prostate cancer 
or are experiencing acute symptoms that may 
suggest prostate disease. Although the value 
of the PSA test as a screening tool is scien-
tifically contentious, the public perception 
of prostate screening is reportedly positive, 
strengths and limitations of this study
 ► Qualitative methodology is well-suited to 
investigating complex multifaceted processes, 
like communicating about prostate-specific 
antigen  (PSA) screening from the perspective of 
clinicians, and preserves important contextual 
information relating to the process.
 ► Data were from a large, rigorously derived sample 
of general practitioners (GPs) from different practice 
types and locations, and in two countries. The four 
approaches identified in this study may be applicable 
to a wide range of practice settings.
 ► It is possible that those GPs who did not participate 
were in some way different to those who did (ie, that 
these data are subject to selection bias); however, 
the diversity in our respondents suggests that it is 
very unlikely that our sample was biased towards a 
particular view of PSA screening or corresponding 
communication style.
 ► As this is a qualitative study, we cannot infer 
prevalence of the four reported approaches; 
the results of this study could be extended into 
quantitative survey research with whole populations 
of GPs to test prevalence.
 ► Public and patient perspectives were not included 
in this study; additional qualitative research might 
explore their experiences of communicating with 
clinicians about prostate screening, to further inform 
policy and practice.
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including an inflated sense of the benefits and underes-
timation of the harms.1 Access to a PSA test is often via 
general practitioners (GPs). The large number of men 
screened in some countries, and the extent of public 
misperception and scientific contention, makes the 
communication between men and their GPs about pros-
tate cancer screening especially important.
Communicating about screening is difficult. In-depth 
discussions about cancer screening can be complex and 
may involve multiple statistical concepts, such as test 
sensitivity and specificity, and absolute and relative risk 
reduction figures from trial-based evidence. Chan et al 
identified >20 specific informational items that experts 
and patients identified for inclusion in an ‘ideal’ discus-
sion about prostate screening.2 The authors synthesised 
the items into a core set of key facts that clinicians should 
provide about PSA screening to their patients (figure 1, 
developed by KP); however, we note that even some of 
these items are contentious or inconsistent with the 
various national guidelines that we will discuss in the next 
section.
Proposed communication standards for PSA screening 
discussions are reportedly challenging to implement 
in clinical practice.3–5 PSA tests are often ordered in 
the absence of any discussion; in the USA, men report 
being unaware of being screened,6 not being asked for 
their screening preferences and undergoing PSA testing 
without first discussing it with their doctor.7 Clinicians 
report offering screening without prior counselling.8 A 
survey of US physicians reported that 20% acknowledged 
ordering PSA without telling patients.9 This can be for 
various reasons.10 Volk et al surveyed US physicians and 
found that those physicians who reported ordering PSA 
tests without discussion were more likely to believe that 
patients wanted to be screened and that education is 
not needed. This was in contrast to those physicians who 
engaged patients in prescreening discussion because they 
believed patients should know about the lack of evidence 
supporting screening.11 Physician beliefs about the limita-
tions of the scientific evidence for PSA screening, the 
questionable utility of the PSA test and ethical concerns 
regarding patient autonomy have also been identified as 
influencing the likelihood of discussions in US studies.10 12 
Physician beliefs can shape the content of discussions; 
in a UK study, the strong personal views of clinicians 
against the value of PSA screening were reportedly clearly 
portrayed in their presentation of information about 
prostate cancer screening.13
In addition to this work on physician knowledge, values 
and attitudes, some researchers have studied patient and 
practice factors that may facilitate or preclude discussions 
about prostate cancer screening. For example, in one 
study US physicians were less likely to discuss screening 
if a patient had already made a decision about screening 
or was perceived to have limited ability to understand the 
information.10 Other studies have reported on factors 
Figure 1 Chan et al identified a core set of key facts that clinicians should include in an ‘ideal’ discussion about PSA 
screening.
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affecting the quality of discussions, including a lack of 
time and the complexity of the topic.9
Clinicians have cited clinical guidelines and scien-
tific evidence about prostate cancer screening as factors 
guiding their practice.13 However, this professional guid-
ance varies widely, which may partly explain the observed 
variation in practice. Table 1 outlines the recommen-
dations of key professional organisations in relation to 
communicating about prostate cancer screening, illus-
trating the main points of difference. ‘Informing’ men 
about the benefits and harms of PSA screening is univer-
sally recommended; and use of decision support tools is 
recommended by half of the professional organisations. 
Only 4 of the 10 guidelines advise whether GPs should 
raise the topic of PSA screening with men who do not ask 
about it in routine consultations. Medico-legal issues are 
referred to in only one, Australian, guideline. In practice, 
clinical guidelines may not always help GPs to decide how 
and what to communicate about PSA screening.14
Entwistle et al characterised the two main ways that 
healthcare organisations communicate with the public 
about screening—Be screened and Analyse and choose—and 
proposed an alternative approach to communicating 
about screening, which they termed Consider an offer.15 The 
Consider an offer approach suggests healthcare providers 
should support people to assess an offer for screening, 
with a recognition that people may reasonably decline 
such offers. Consider an offer guides clinicians and patients 
to consider the source of screening recommendations 
and professional guidance. We return to the Consider an 
offer approach in the ‘Discussion’ section.
This study draws on a larger body of work investi-
gating clinicians’ approaches to, and reasoning about, 
PSA screening in Australian and UK general practice. 
Despite similar levels of prostate cancer mortality, both 
PSA screening and prostate cancer incidence are lower in 
the UK than in Australia.16–19 Previous analyses from this 
study have illuminated systemic variation between the two 
jurisdictions, including in payment models, the history 
of PSA screening policy, screening culture and referral 
patterns.14 The authors have also published earlier find-
ings from the empirical work about how clinicians manage 
the potential for overdiagnosis20 and their responses to 
uncertainty in relation to prostate screening.21 Table 2 
summarises our previous findings regarding differences 
in PSA screening in the two jurisdictions. Note that 
Table 1 Recommendations of professional organisations in terms of communicating about prostate screening




PCFA/CCA NHMRC RACGP USANZ NICE NHS/PHE USPSTF ACS NCI AUA
Is GP advised about whether to 
raise the topic with men if men 
do not raise it first?
✓ ✓ ✓ ✓
Is a decision aid 
recommended?
✓ ✓ ✓ ✓ ✓
Is a decision aid provided? ✓ ✓
Is IDM* recommended? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Is SDM† recommended? ✓ ✓ ✓ ✓
Is guideline accompanied by a 
clinician information sheet?‡
✓ ✓ ✓ ✓
Is guideline accompanied by a 
patient information sheet?§
✓ ✓ ✓ ✓
Does guideline recommend 






*The patient is presented with all the information pertinent to making a decision and then assumes final authority for the decision.30
†The patient is provided with all the relevant information and works with the healthcare provider to reach a decision that reflects the health 
preference of the patient.30
‡A clinician information sheet is a fact sheet summarising the evidence of benefits, limitations and associated risks of prostate screening to 
help clinicians to accurately inform men.
§A patient information sheet is a fact sheet outlining the benefits, limitations and associated risks of having a PSA test for prostate cancer 
risk.
ACS, American Cancer Society; AUA, American Urological Association; GP, general practitioner; IDM, informed decision making; NCI, 
National Cancer Institute of the National Institutes of Health; NHMRC, National Health and Medical Research Council; NHS/PHE, National 
Health Service/Public Health England; NICE,  National Institute for Health and Care Excellence; PCFA/CCA, Prostate Cancer Foundation of 
Australia/Cancer Council Australia; PSA, prostate-specific antigen; RACGP, Royal Australian College of General Practitioners; SDM, shared 
decision making; USANZ, Urological Society of Australia and New Zealand; USPSTF, United States Preventive Services Task Force.
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prostate cancer screening is not recommended in either 
location.
In the light of our prior findings on variation between 
the Australian and UK contexts, we set out to better 
understand GP communication practices in particular. 
The larger programme of study examined the role of 
values, ethics, context and evidence in cancer screening 
policy and practice. In this paper, we present an anal-
ysis of how GPs in Australia and the UK explain their 
approach to communication with men about prostate 
cancer screening. We asked the following research ques-
tions in respect of both settings:
1. How do GPs describe their communication with men 
about prostate cancer screening?
2. What are the reasons given by GPs for communicating 
with men as they do?
3. Why and under what conditions do GPs 
communication approaches vary?
MethOds
GPs had an opportunity to discuss the study with KP 
prior to participation; all GPs provided informed written 
consent to participate and were compensated $A100 for 
their time. Participation was voluntary, participants could 
withdraw at any time and confidentiality was protected. 
All responses were anonymised before analysis and poten-
tially identifying information removed.
design
We applied the well-established, systematic qualitative 
research methodology of grounded theory.22 Grounded 
theory is a method of conducting qualitative research 
that focuses on creating conceptual frameworks or theo-
ries through building inductive analysis from the data. 
All study authors have been formally trained in quali-
tative research methods; SC has particular expertise in 
grounded theory methodology.
Participants and setting
We identified clinicians working in primary care prac-
tices as being in the best position to provide insight on 
our research questions, and most likely to face the ques-
tion of PSA screening as part of their everyday practice. 
We purposively recruited a sample of GPs first in the 
Australian healthcare setting, and later in the UK 
Table 2 Organisation and occurrence of prostate-specific antigen (PSA) screening in Australia and the UK 
Australia UK
For men asking about 
prostate screening
 ► PSA screening is available. GPs are advised to 
offer evidence-based decisional support to men 
considering whether or not to have a PSA test, 
including the opportunity to discuss the benefits 
and harms of PSA screening before making the 
decision.
 ► PSA screening is available, but with conditions. 
The National Health Service Prostate 
Cancer Risk Management Programme has 
recommended that screening for prostate 
cancer be available for asymptomatic men, on 
the understanding that they have been provided 
with full and balanced information about the 
advantages and limitations of the PSA test.
Screening frequency  ► GPs reported frequently providing PSA 
screening within routine consultations.
 ► GPs reported often initiating discussion of PSA 
screening; GPs reported commonly receiving 
requests for PSA screening.
 ► GPs reported that PSA screening was rare in 
practice.
 ► UK GPs reported not promoting PSA screening; 
they also reported that men rarely asked for 
PSA screening.
Guidance for GPs  ► GPs are free to practice according to individual 
standards.
 ► Australian guidance was mixed (see table 1). The 
National Health and Medical Research Council 
has recently issued guidance to Australian GPs 
to drive greater consistency in practice.
 ► Government-issued standards for PSA 
screening and communication processes in 
clinical settings are in place.
 ► Guidance has been distributed to all GPs in 
England and Wales to assist in the provision of 
information to men.
 ► GPs can choose to follow issued guidance but 
seem inclined to operate within the bounds of 
their health system.
Preferred form of 
information provision
 ► GPs reported generally informing men via a 
verbal discussion of PSA screening.
 ► GPs reported relying on a standardised printed 
information leaflet. This was central to the 
consultation, sometimes alongside a brief verbal 
discussion.
Appointment structure  ► PSA screening tests were usually discussed and 
ordered in a single appointment.
 ► Information-giving occurred in a separate 
appointment to PSA screening itself.
Summary of findings and details reported in Pickles et al 2016.
GP, general practitioner.
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(England, Scotland and Wales), as our study evolved. 
Sampling for the broader study was initially driven by 
existing quantitative evidence on characteristics of GPs, 
patients and practice contexts associated with higher or 
lower PSA screening rates. We aimed to recruit a set of 
GPs likely to have diverse practices. See Pickles et al14 for a 
detailed description of the recruitment process.
In Australia, we advertised in newsletters and email lists 
of GP organisations, in mass and social media, medical 
journals, we phoned practice managers and via email and 
flyers distributed by rural GP organisations. In the UK, 
academic colleagues distributed an invitation through 
their professional networks, we advertised to members 
of the Royal College of General Practitioners (RCGP), 
primary healthcare departments, university academic 
departments, and general practice and research via 
mail lists, and in organisational newsletters including 
the Society for Academic Primary Care and RCGP 
Scotland’s eBulletin. GPs were invited to contact KP if 
they were interested and willing to participate. An infor-
mation sheet outlining the research project was emailed 
to all respondents. All GPs who expressed interest in 
participating were included.
Overall, 69 GPs participated in this study, 40 GPs in 
Australia and 29 GPs in the UK. 44/69 of the GPs were 
male. The GPs ranged in clinical experience, working 
from 1 to 40 years in general practice, and were located 
in both metropolitan (n=32/69) and regional/rural 
(n=37/69) clinics, with varied patient populations.
data collection
The field work for the prostate cancer element of this 
study was conducted by KP, a public health researcher, 
as part of a PhD degree. KP had no immediate personal 
or professional experience with prostate cancer or PSA 
screening.
We generated data via in-depth semistructured inter-
views. An interview guide was prepared to provide general 
direction and an overview of potential question routes. 
The interview guide covered a broad range of topics, 
including GPs’ recent clinical encounters involving PSA 
screening decisions, communicating information about 
the PSA test to patients; screening pathways and overdiag-
nosis of prostate cancer. Example questions asked about 
communication included
 ► Describe a recent consultation with an asymptomatic 
man involving the PSA test … Can you take me right 
back to the beginning and tell me as much as you can 
about the consultation. Who initiated the conversa-
tion about the PSA test?
 ► Should men be informed about overdiagnosis, false 
positives before having a PSA test?
 ► How well do you think men understand PSA screening?
The schedule was reviewed and modified between 
interviews based on the developing analysis to enrich 
the data available to answer our research questions. 
All GPs were asked to think back to their most recent 
consultation involving a discussion about PSA screening 
or to describe a typical consultation where the topic was 
raised.
Interviews took place between March 2013 and June 
2014 (Australian GPs) and between September and 
December 2014 (UK GPs). We continued to interview GPs 
until we judged we had reached theoretical saturation; 
that is, the point at which gathering more data ceases to 
yield any further insights about the emerging grounded 
theory. All interviews were conducted by KP, primarily 
by telephone or Skype, and ranged in duration from 
18 to 70 min. With GP permission, the interviews were 
audio-recorded and transcribed verbatim by a profes-
sional transcribing service to produce data for anal-
ysis. Transcripts were not returned to participants for 
comment; all participants will receive a written summary 
of the research findings on study completion.
data coding and analysis
The analysis was led by KP, who coded the transcripts. A 
subset of transcripts was read and coded by three authors 
independently to ensure interpretive rigour. We coded to 
capture the range of variation in the GP-reported discus-
sions about PSA screening and for conditions that could 
explain that variation. Codes were kept as similar to the 
data as possible to preserve context and to ensure that 
all concepts derived directly from the data. Codes were 
compared and discussed to inform the development of the 
central concepts in the study. KP wrote detailed memos 
during data collection and analysis which were reviewed 
and discussed by the authors in analysis meetings.
results
We observed considerable diversity in the ways that GPs 
described their communication about prostate cancer 
screening. Although the majority of variation occurred 
among Australian GPs, we also report on data from the UK 
because this helps illuminate the contrasting complexity 
of the Australian data, including the role of local context.
We first explain how Australian GPs varied in their 
descriptions of their communication. We then consider 
important ways in which UK and Australian GPs were 
similar and different.
Australian GPs’ accounts of communicating with men about 
prostate cancer screening
Australian GPs’ accounts varied greatly in how they intro-
duced conversations about PSA screening with men, how 
screening discussions were framed and their perceived 
informational obligations.
screening men with little or no prior communication
A minority of interviewees reported ordering PSA tests 
for asymptomatic men with little or no prior commu-
nication with the patient. GPs were categorised as 
non-communicative if they reported (1) ordering 
PSA tests without explaining that to their patient, (2) 
ordering PSA tests at patient request with no further 
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discussion or (3) explaining PSA screening only after 
a positive PSA test result. We encountered occasional 
practices from which asymptomatic men were mailed 
pathology forms for a PSA test via practice recall 
systems, bypassing a GP consultation and opportunity 
for discussion.
Several possible justifications were provided by 
non-communicative GPs:
 ► Some GPs reasoned that because the information 
about PSA screening was ‘confusing’ ‘complicated’ 
and potentially contradictory, it should not be 
provided.
 ► Some GPs said their role was to ensure that men could 
be screened if they wanted, ‘I see doctors purely as 
enablers, of what people want … If you don't want to 
read about it [the test], then fine; I’ll just order one 
for you’ (AGP17).
 ► Some GPs considered it ‘up to each patient to be 
informed appropriately’ (AGP14); if a man requested 
a PSA they would order a test assuming that man felt 
sufficiently informed from other sources.
 ► Some GPs considered it unnecessary to provide infor-
mation unless the man received a cancer diagnosis, 
‘I don’t think they need all that information at the 
level of PSA testing. I think, that once you’ve got your 
cancer diagnosis, you can talk about what you want to 
do with that then’ (AGP26).
 ► Some GPs did not appear to have a complete under-
standing of the epidemiological data, for example, 
‘someone was saying that a certain number of people 
had to have radiation and surgery and have impo-
tence and incontinence, for one person’s life to 
be saved. I mean—I don’t know how you get those 
figures’ (AGP2).
These were, however, minority views. We focus in what 
follows on the majority of GPs who did communicate with 
men in some way about PSA screening.
Communicating with men, with variation on three key 
dimensions
We identified three dimensions central to GP discussions 
with men about PSA screening:
1. The GPs’ primary communication goal. Some GPs 
had the goal of convincing the patient to screen, some 
had the goal of convincing the patient not to screen, 
and some had the goal of supporting decisions or fa-
cilitating patient choice.
2. The type of information the GP provided.
3. The type of patient understanding the GP sought to 
achieve.
It appeared that dimension 1 was dominant; GPs 
communicated in accordance with their preferred goal 
or outcome of the communication. In most cases, the 
GP’s positioning on dimensions 2 and 3 was grounded 
in whether the GP felt strongly that patients should be 
screened or not, and the degree to which they directed 
men towards that preference. Below we explain these 
three dimensions and GPs’ reasoning about them.
Dimension 1: GPs’ primary communication goal
Some GPs aimed to convince men either to agree to be 
screened or to agree not to be screened. These GPs had 
strong beliefs regarding whether or not PSA screening 
should occur routinely, and wanted patients to follow 
their advice, their ‘guide … down the path’ towards what 
they ‘thought was best’ (AGP29). GPs acknowledged ‘bias 
will creep into that’ (AGP29); ‘you can’t help yourself but 
… what you believe in is the way you push the consul-
tation’ (AGP18). However, this approach was justified by 
beliefs that ‘… you can only do what you think is best 
for the patient’ (AGP29) and ‘a lot of people do want to 
be told what to do … doctors are their reference point’ 
(AGP31). GPs recognised that men sometimes chose not 
to take the advised pathway, for example, ‘there are times 
when it wouldn’t matter what you said to a patient they’re 
still determined to have the test’ (AGP18).
An alternative communication goal was to support men 
to make decisions about screening consistent with their 
own values and preferences. GPs with this goal aimed to 
facilitate an informed decision-making process and were 
determined to provide information to all men ‘to make 
up their own mind’ (AGP16), because ‘with the PSA test, 
I can’t so easily say to myself, well, it’s in your best interests 
so I don’t need to inform you properly’ (UKGP9). GPs 
with this goal reasoned that a man ‘should be empowered 
to know everything’ (UKGP28); ‘should have the right 
and want to be able to make that decision for themselves 
about whether they have the test or not’ (AGP5).
Dimension 2: GPs’ reported information provision
Because GPs had different goals in communicating, 
they provided different information, in both quality and 
quantity.
Some GPs claimed to provide men with ‘complete’ and 
‘unbiased’ information because they considered it their 
‘ethical obligation’ as a health professional to do so; the 
patient, in this view, had a ‘right’ to be fully informed, 
so GPs should ‘[put] all the information on the table’ 
(AGP31); ‘I’m very keen that people are well-informed 
about really what it means if they are to undertake a PSA 
rather than just simply agreeing to what their idea might 
be’ (UKGP23). This sometimes extended to teaching 
patients how to locate and interpret information for them-
selves. Informing patients was described by some GPs as 
serving a self-protective legal purpose, ‘I’ve informed the 
patient, the patient made his own decision, so he’s got to 
then accept the consequences’ (AGP19).
In contrast to GPs who sought to provide comprehen-
sive information, other GPs filtered information to ‘actu-
ally tell them [patients] what counts the most’ (AGP4). 
Here GPs aimed to explain their own best judgement 
about the evidence, framing the evidence according to 
the GP’s opinion regarding the value of PSA screening. 
This often took the shape of a personal recommendation 
either to have a PSA test or not. One GP, for example, 
said ‘[patients] don’t have that knowledge so you sort of, 
give an explanation why it needs to be done’ (AGP35); 
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another, in contrast, thought ‘my discussing it has prob-
ably been biased towards not getting it done’ (AGP16). 
Some GPs considered such advising to be best practice 
because information provision alone was not enough to 
help men decide what to do. For example, one GP who 
favoured PSA screening reasoned, ‘If they really don’t 
know what to do then [after receiving information], any 
doctor would be a fool not to say look, get it investigated 
because, the most stupid thing anyone could do is say 
oh don’t bother about it … that’s just a total recipe for 
disaster’ (AGP31).
Dimension 3: GPs’ reported ambitions for men’s understanding
All GPs aimed to support the development of patient 
understanding. However, there were two different concep-
tions of what constituted appropriate understanding of 
the information presented and available options:
1. Sometimes GPs aimed to assist men to develop de-
tailed population-level understanding of the evidence. 
They wanted men to understand all aspects of the 
information provided and described checking un-
derstanding, identifying gaps in patient knowledge, 
and clarifying misunderstandings, because ‘I don’t 
think their pre-existing understanding of the test is 
very good at all in most cases’ (UKGP21). Some of 
these GPs reported feeling personally and profession-
ally responsible for presenting the ‘right amount’ and 
‘right level’ of information for individual patients, 
‘[achieving understanding is] really the doctor’s job, 
and our skill in trying to explain all that complicat-
ed evidence, as best as we can’ (AGP19). Some GPs 
commented they hoped men understood the detail of 
the evidence, otherwise it indicated they as a GP had 
done a ‘bad job of explaining it’ (AGP6); however, 
they also explained ‘it’s a very difficult thing to for-
mally confirm that they understand the implications 
of having the test done without kind of interrogating 
them’ (UKGP1).
2. Alternatively, GPs might aim for men to develop over-
all ‘gist’ understanding. GPs committed to ‘gist’ un-
derstanding were satisfied if their patient had a less 
complete grasp of the intricacies of the evidence base 
as long as they had an overall understanding of what 
the GP perceived to be core issues; ‘I feel like as long 
as they can understand that basic concept [in this in-
stance, that PSA is not a perfect test] … then I feel like 
it’s okay to still do the testing, even if they don’t un-
derstand all the detail … I feel like that’s a reasonable 
level of understanding, I don’t feel like people need to 
have an absolutely thorough kind of understanding’ 
(AGP5). Those GPs who thought ‘gist’ understanding 
was acceptable thought it was reasonable for men to 
trust their doctor to advise them appropriately.
relationship between the dimensions
When taking account of the three dimensions along which 
GPs varied, we identified four overarching approaches 
to communication: (1 and 2) Be screened and Do not be 
screened (GPs who guided men towards screening or not 
screening); (3) Analyse and choose (GPs who aimed to 
ensure men made their own independent, informed deci-
sion, based on a detailed population-level understanding); 
and (4) As you wish (GPs who simply facilitated the man’s 
stated preference to be screened or not screened). Two 
of these terms (Be screened and Analyse and choose) align 
with Entwistle et al’s characterisation of communication 
approaches,15 as outlined in the introduction. Each GP 
we interviewed had a general preference to employ one 
of these four approaches in their everyday communica-
tion about PSA screening. In table 3, we present an inte-
grated illustration of the characteristics of each approach, 
ordered according to the three key dimensions evident in 
the GP accounts.
Be screened or Do not be screened interactions
If GPs had a strong preference that men should either 
be screened or avoid screening, they communicated in 
a directive way, oriented to encouraging the man either 
to screen or avoid screening respectively. This included 
offering personal judgement about the value—or 
harms—of PSA screening or framing the information 
they provided towards or away from screening. Some GPs 
gave a recommendation without offering men any further 
information. In Be screened and Do not be screened interac-
tions, GPs considered it sufficient that men developed gist 
understanding of the information provided because they 
thought it was reasonable for men to trust their doctor to 
advise them appropriately. These GPs strongly believed 
either that men should be screened routinely, or that they 
should not be screened at all, and they wanted patients to 
follow their advice.
Analyse and choose interactions
If GPs aimed to support men to make their own decisions, 
consistent with the man’s personal preferences (ie, a 
patient-directed decision), then they were not directive in 
their communication. In these interactions, GPs aimed to 
provide a comprehensive and impartial summary of the 
best available evidence; their goal was to ensure that men 
developed a detailed population-level understanding of 
their options in order to make an informed decision. 
They saw this as a neutral, educative role. For some, this 
approach was protective against potential medico-legal 
threats. GPs using this approach may personally favour 
either screening or not screening, but their primary 
commitment was to support the man’s decision, regard-
less of their own professional beliefs about screening.
As you wish interactions
Sometimes GPs acted on patient wishes to be screened or 
not screened without questioning. In these interactions, 
GPs did not attempt to direct men in any particular direc-
tion, and often provided little information, ensuring that 
the man understood PSA screening was not a priority. In 
some cases, GPs perceived men to have already made a 
screening choice based on personal preference or gist 
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understanding. These consultations typically involved 
men with an already-established screening preference, 
mostly for screening; the GP simply acted in line with the 
man’s instructions.
how GPs negotiate communicating within specific contexts
Many Australian GPs reported discussing PSA screening 
with men often, so had a prepared basic ‘spiel’; as one 
reported, ‘the PSA is such a common question that you 
get asked and you just have to have some idea in your 
head what you’re going to say when they come in’ 
(AGP18). This spiel could be tailored to specific contexts 
as necessary. GPs’ interviews indicated that they tended 
to have a preferred approach for most PSA interactions 
(to guide patient towards screening or not screening, 
to support men to make their own decision or to act in 
accordance with the man’s expressed preference) or that 
they had maintained a particular communication style 
over time. However, we identified 11 situational and rela-
tional factors (see table 4) that GPs described as tempo-
rarily shifting their usual or preferred communication 
goals and processes. These factors predominantly arose 
from specific circumstances of individual consultations. 
GPs described modifying their provision of information 
and/or advice, depending on the 11 factors described in 
table 4.
GPs also shifted between the four communication 
approaches more readily when they were presented with 
complex cases; producing more fluid, responsive and 
sometimes ‘quite inconsistent’ (AGP16) conversations. 
Many GPs did have a primary goal when communicating 
(to encourage or discourage screening, or to support the 
man to make his own decisions) but these could change 
in different situations. Also, some men did not take 
the advised pathway—either towards screening or not 
screening, or some men preferred the GP to direct the 
decision, not wanting to engage with information or to 
make their own decision.
Comparison of communication approaches in Australia and 
the uK
UK GPs generally did not communicate about PSA 
screening unless men asked about it, so they often 
neither communicated about it as a screening test, nor 
ordered it. When men asked for a PSA test, information 
provision was central to consultations in the UK context, 
and most UK GPs commonly practised according to the 
Analyse and choose or Do not be screened approaches. Few UK 
GPs described adjusting their conversations about PSA 
screening with patients.
The reported consistency of PSA communication 
practices in the UK contrasted strongly with the significant 




 ► GP strongly believed that the man should be screened
 ► GP’s goal is to convince the man to screen
Do not be screened interactions
GP’s primary goal:
 ► GP strongly believed that the man should not be screened
 ► GP’s goal is to convince the man not to screen
Information provided by GP:
 ► GP’s personal judgement about the value of PSA screening
 ► GP either tailored information provided to men to encourage 
men to be screened or did not provide information (provided 
only encouragement to be tested)
Information provided by GP:
 ► GP’s personal judgement about the harms/downsides of 
PSA screening
 ► GP either tailored information provided to men to 
discourage screening or did not provide information 
(provided only encouragement to avoid testing)
Type of understanding that GP considered adequate:
 ► Gist understanding of information provided
Type of understanding that GP considered adequate:
 ► Gist understanding of information provided
Analyse and choose interactions
GP’s primary goal:
 ► GP may personally support testing or not testing
 ► Despite their personal beliefs about testing, GP’s goal is to 
help the man to make his own informed decision
As you wish interactions
GP’s primary goal:
 ► GP may or may not have a strong position on the value of 
PSA screening
 ► GP’s goal is simply to follow the man’s expressed 
preference
Information provided by GP:
 ► GP aimed to provide a comprehensive and impartial 
summary of best available evidence
Information provided by GP:
 ► GP provided little information
Type of understanding that GP considered adequate:
 ► GP’s goal was to ensure men developed detailed 
understanding of their options, to make own informed 
decision
Type of understanding that GP considered adequate:
 ► Ensuring men understood was not a priority for the GP; 
in some cases, GP perceived men to have already made 
a screening choice based on personal preference or gist 
understanding
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variation reported in the Australian context (tables 3 
and 4). The contextual factors considered in table 4 
were uncommon in UK GPs’ accounts due to fewer men 
requesting and fewer GPs suggesting prostate screening. 
UK GPs mostly reported giving the same standard infor-
mation leaflet to all men who expressed interest in PSA 
screening, regardless of their personal circumstances. 
Many GPs practising in Australia tended to filter informa-
tion, and commonly practised according to the Be screened 
approach, but no UK GPs reported using this approach.
We identified different versions of the Do not be screened 
approach adopted by Australian and UK GPs. For the 
Australian GPs, this approach took the form of a personal 
recommendation against screening, directed by the GP 
and according to their personal—negative—perspec-
tive of PSA screening. For UK GPs, the Do not be screened 
approach also involved the GP recommending that the 
man should not be screened. However, UK GPs explained 
this as enactment of a collective standard of care recom-
mended and issued by the UK National Health Service 
irrespective of their own personal preferences for or 
against screening.
dIsCussIOn
This analysis suggests that GPs’ primary communication 
goals are a central component of consultations about pros-
tate screening. Four distinct communication approach-
es—Be screened, Do not be screened, Analyse and choose, and As 
you wish—were identifiable from GPs’ accounts of their 
preferred practice.
The terms Be  screened and Analyse and choose align with 
Entwistle et al’s Consider an Offer framework. We identi-
fied two additional ways of communicating unique to our 
empirical data, which we labelled Do not be screened and 
As you wish. The need for inclusion of a Do not be screened 
element is likely a product of the Australian context 
where the PSA test is available and widely promoted for 
screening purposes in the media, despite the majority of 
relevant public health and health professional groups 
recommending against routine screening of asymp-
tomatic men. This meant Australian GPs were regularly 
consulted by men expecting to be screened, and some 
reported feeling obligated to actively direct men away 
from wanting a PSA test for that purpose.
The As you wish category is also likely to be, in part, 
a reflection of the somewhat market-driven Australian 
healthcare system. As you wish interactions occurred when 
GPs’ believed men had already made up their minds 
about their preferred choice and could not be swayed by 
information presented by the GP. This led GPs to imple-
ment the man’s choice and order the test despite the lack 
of an evidence base to support that decision. There was no 
evidence of As you wish interactions in the UK data. As we 
previously reported,14 in the UK there is strong guidance 
to GPs to practice in a particular way. GPs are expected 
to steward limited National Health Service resources, and 
the PSA test is not publicly promoted to the same extent, 
limiting consumer expectations for screening. All of these 
are conceivable explanations for why As you wish interac-
tions were less commonly reported in UK interviews.
the main issues raised by this analysis
The four variants raise important questions about 
patient-centred care, consumer demand and the role 
of the health professional. It is well established in the 
literature that both patients and clinicians are rarely 
entirely rational, and may not necessarily know what 
is in the patient’s best interest, particularly when 
faced with scientific uncertainty.23 24 Humans tend, for 
example, to become sensitised to worst-case scenarios 
and disregard objective risk probabilities; this makes us 
vulnerable to pursuing, recommending or accepting 
potentially harmful treatments.25 If this is so, an As you 
wish approach could mean patients are more exposed to 
increased harms, and that leaving patients to make deci-
sions about their healthcare needs without professional 
guidance is potentially maleficent, or at least negligent. 
This problem is further complicated by the wide avail-
ability of possibly misleading information, provided by 
sources that have an interest in inflating perceptions 
of cancer risk. Some authors highlight that increased 
patient involvement in decision making has potential 
for negative social consequences such as increasing 
patient demand for unproven services.26 Cribb and 
Entwistle reasonably argue that in some circumstances 
it may be ethically legitimate for health professionals to 
question and even influence the preferences of patients 
for these reasons.27
Most current recommendations encourage GPs 
to discuss the benefits and harms of prostate cancer 
screening with patients. However, there may be consider-
able variation in what patients want and expect from GPs 
prior to making a decision about PSA screening. Degeling 
et al ran three community juries on the topic of how GPs 
should communicate about PSA screening. Juries heard 
extensive expert evidence about PSA screening, consent 
and general practice. Two juries of general citizens 
(ie, mixed gender and age) concluded that GPs should 
ensure men have enough knowledge to make their own 
decision. One jury of only men of PSA screening age 
concluded that men should be able to trust their GP 
(or a specialist) to provide just enough information at 
just the right time, expressed concern about the poten-
tial for information overload, and thought the degree 
of patient involvement depended on the patient.28 
This suggests that citizens who are (atypically) well-in-
formed about the benefits and harms of prostate cancer 
screening may take different views and have different 
expectations on how GPs should communicate about 
PSA screening. If this is the case, it may be appro-
priate for GPs to have at least a range of communica-
tion strategies available, to suit the needs of different 
patients. Men eligible for, or already receiving, PSA 
screening may well prefer for GPs to direct the decision 
(Be screened or Do not be screened approaches) to avoid 
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uncertainty. However, men’s preferences are arguably 
an insufficient guide; other considerations, including 
clinical practice guidelines, medical law and clinical 
ethics requirements, are relevant to determining what 
GPs should do.
A large component of this analysis is about aware-
ness of and sensitivity to context and the importance 
of interpersonal relations and their influence on 
communication practice (see table 4). Some of the 
GPs’ communication decisions, based on situational 
or individual factors, were easily justified because the 
situation presented was either clinically relevant (eg, 
family history, older age) or professionally justified 
(eg, low literate patient, patient request). While most 
guidelines advising on PSA screening suggest informed 
or shared decision making, they do not consider what 
may be a ‘best’ approach to situations involving the 
many local factors that GPs’ face in day-to-day practice, 
including relational factors, implicated in screening 
decisions (and the complexities of general practice). 
We identified a subtle web of relational issues that 
influenced GPs to move between communication 
options and particular types of decision pathways. 
These included managing colleague associations (what 
are GPs to do about patients who have come from a 
pro-screening GP to a GP who does not support PSA 
screening?), managing business, including patient 
lists (patient request, time pressures) and maintaining 
patient trust. These issues made the decision-making 
process particularly complicated, and in addition to 
vague guidance on such matters, perhaps account for 
why many GPs appeared to have multiple, dynamic 
approaches. Accounting for relational variables as 
identified in this study can facilitate nuanced assess-
ment of the different types of support clinicians might 
offer people who may struggle with particular deci-
sions29 and allows scope for professional expertise: the 
‘art’ of medicine.
Implications for policy and practice
There are variable approaches to communication about 
PSA screening, some of which may be considered better 
than others. Guidance about communication—not just 
about the PSA test itself, but also about how best to 
facilitate the decision—may be useful; we suggest there 
is a need for further higher-level professional discus-
sions about what the primary goals of GPs should be 
when communicating about PSA screening. Coming to 
an explicit agreement on what that purpose should be 
may assist in improving communication and providing 
clearer guidance for GPs working in the Australian 
context. For instance, one endpoint (that could be eval-
uated) may be that men can demonstrate they have a 
sense of their values in relation to the available options, 
to show evidence of rational, thoughtful and informed 
decision making.
limitations
As this is a qualitative study, we cannot infer the prev-
alence of the reported approaches to communication; 
the results of this study could be extended into quanti-
tative survey research with whole populations of GPs to 
test prevalence. It is also possible that those GPs who did 
not participate were in some way different to those who 
did (ie, that these data are subject to selection bias); 
however, the diversity in our respondents suggests that 
it is very unlikely that our sample was biased towards 
a particular view of PSA screening or corresponding 
communication style.
COnClusIOn
This empirical study produced evidence documenting 
varied approaches to communication. The reported 
consistency of PSA communication practices in the UK 
contrasted strongly with the significant variation reported 
in the Australian context. In the Australian setting, some 
flexibility in communication seems justified. Further, 
because of (1) the large number of men implicated, 
(2) the known harms of the screening process and (3) 
that PSA is not a routine screening programme, we 
argue that PSA screening is a particularly pressing case 
to necessitate dedicated effort to facilitate conversa-
tions that include but go beyond potential harms and 
benefits with men. This would include encouraging and 
enabling men who ask for screening to look carefully 
at why PSA screening is not recommended (to increase 
awareness of why a Do not be screened approach is justi-
fied). Assisting GPs to facilitate these conversations with 
patients should offer the advantage of supporting men’s 
autonomy and reducing harm.
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